Writing the Methods Section for Medical Manuscripts: ICMJE & CONSORT Compliance Guide 2026

Writing the Methods section of a medical manuscript is not simply a matter of describing what happened during a study. It is the section that allows editors, peer reviewers, and other researchers to determine whether the study was appropriately designed, ethically conducted, statistically sound, and sufficiently transparent to be reproduced.

A weak Methods section can create serious problems even when the underlying research is strong. Missing details about participant selection, data collection, ethics approval, outcome definitions, statistical analysis, or trial registration can trigger reviewer queries, editorial delays, or rejection.

For authors preparing clinical research for publication in 2026, the standard is increasingly clear: write the Methods section so that a knowledgeable researcher with access to the underlying data could understand how and why the study was conducted and reproduce the analytical approach. The ICMJE explicitly identifies clarity, reproducibility, ethics, technical detail, and appropriate statistical reporting as core principles for Methods sections.

This guide explains how to write a Methods section for a medical manuscript, with particular attention to ICMJE recommendations and CONSORT reporting expectations for randomized clinical trials.

💡 Need expert help with your paper?
Transform your manuscript with ManuscriptLab’s professional editing & formatting services!

What Is the Purpose of the Methods Section?

The Methods section answers four fundamental questions:

1. What was studied?
2. How was the study conducted?
3. How were outcomes and variables measured?
4. How were the data analyzed?

The ICMJE states that the Methods section should provide enough detail for others with access to the data to reproduce the results. It should primarily describe information that was available when the study plan or protocol was developed; findings generated during the study belong in the Results section.

Think of the Methods section as the manuscript’s technical audit trail. A reviewer should not have to infer how participants were selected, what constituted the primary outcome, which statistical model was used, or whether an ethics committee approved the research.

What makes a Methods section publication-ready?

A strong Methods section should be:

• Specific: Replace vague descriptions with measurable criteria.
• Reproducible: Identify procedures, instruments, software, and analytical methods.
• Chronological: Present the study workflow in a logical order.
• Ethically transparent: Report ethics approval and consent appropriately.
• Statistically complete: Explain the analysis sufficiently to assess its appropriateness.
• Guideline-aligned: Use the reporting guideline appropriate to the study design.
• Consistent: Ensure the Methods, Results, tables, figures, protocol, and registration record do not contradict one another.

1. Identify the Clinical Study Design Before Writing

The first step in writing a methodology section for medical research is to identify the exact study design.

Do not begin by copying a generic “Materials and Methods” template. The reporting requirements depend heavily on whether the research is a randomized clinical trial, cohort study, case-control study, cross-sectional analysis, diagnostic study, systematic review, or another design.

The ICMJE recommends reporting guidelines according to study design, including CONSORT for randomized trials, STROBE for observational studies, PRISMA for systematic reviews and meta-analyses, and STARD for diagnostic accuracy studies.

Match the design to the reporting guideline

The reporting guideline does not replace the journal’s author instructions. Treat the guideline and journal requirements as complementary layers of the submission workflow.

Common pitfall

Do not confuse reporting compliance with study quality. A CONSORT checklist cannot repair inadequate randomization, an underpowered study, poor outcome measurement, or inappropriate statistical analysis. Reporting guidelines improve transparency; they do not substitute for methodological rigor.

2. Describe the Study Population and Participant Selection

Your Methods section should make it possible to understand who entered the study, why they were eligible, and how they were selected.

State:

• Study setting and location
• Recruitment period
• Eligibility criteria
• Exclusion criteria
• Sampling method
• Participant source
• Recruitment procedures
• Relevant baseline characteristics defined before analysis
• Number of participants planned and enrolled, where applicable

For a retrospective study methods section, specify the database, medical record system, registry, institution, or other source from which the data were obtained. Define the study period precisely.

For example, instead of:

“Patients with diabetes were included.”

write:

“We retrospectively identified adults aged ≥18 years with type 2 diabetes who received care at [institution] between January 2022 and December 2024 and met the prespecified eligibility criteria.”

The second version identifies the population, age threshold, design, setting, and timeframe.

Why this matters

Participant selection directly affects external validity and selection bias. Reviewers need to know whether the sample represents the population described in the research question.

Industry-standard metric

For clinical studies, participant flow should be traceable. Randomized trials should clearly distinguish participants assessed for eligibility, randomized, allocated to intervention groups, followed up, and included in the analysis.

For retrospective research, clearly define the source population and the criteria used to construct the analytic cohort.

3. Explain Data Collection Methods in Medical Research

The phrase “data were collected retrospectively” is rarely sufficient.

A robust description of data collection methods in medical research should explain:

• Where the data came from
• Who collected or extracted the data
• Which variables were collected
• How variables were defined
• When measurements were performed
• What instruments or equipment were used
• Whether standardized protocols were followed
• How missing data were handled
• Whether data extraction was independently verified

ICMJE specifically recommends identifying methods, equipment, and procedures in sufficient detail to allow reproduction. For established methods, cite the appropriate reference; for new or substantially modified methods, describe them and explain why they were used.

Example structure

Data source: Electronic medical records from three tertiary-care hospitals.

Extraction period: January 2021 through December 2024.

Variables: Demographic characteristics, comorbidities, laboratory measurements, medication exposure, primary outcome, secondary outcomes, and follow-up status.

Data quality: A predefined extraction form was used, and 10% of records were independently reviewed for accuracy.

This level of specificity allows reviewers to evaluate potential information bias and measurement error.

Common pitfall

Avoid introducing data-cleaning decisions after describing the analysis as though they were part of the original protocol. Distinguish prespecified methods from exploratory decisions.

Also read: 10 Key Reasons Manuscripts Get Rejected Before Peer Review

4. Define Outcomes and Variables Precisely

A Methods section becomes difficult to evaluate when outcomes are described using broad clinical language.

Define the:

• Primary outcome
• Secondary outcomes
• Exposure variables
• Predictors
• Covariates
• Potential confounders
• Effect measures
• Follow-up period
• Time points for assessment

For each major outcome, state how it was measured and when.

For example:

“The primary outcome was 30-day all-cause readmission, defined as an unplanned hospital admission occurring within 30 days of discharge.”

This is substantially stronger than:

“Readmission was assessed after discharge.”

Why definitions matter

Outcome definitions determine what your statistical analysis actually estimates. Ambiguous definitions can introduce misclassification and make studies difficult to reproduce or compare.

For clinical trials, align the Methods section with the protocol and trial registry. If the registered primary outcome differs from the manuscript, editors may question selective outcome reporting.

5. Write the Ethics and IRB Approval Statement Correctly

An IRB approval methods section should provide more than a generic statement that “ethical approval was obtained.”

The ICMJE’s current recommendations state that authors should obtain approval from an independent local, regional, or national review body, such as an ethics committee or institutional review board, and should be prepared to provide documentation if editors request it. The current ICMJE guidance also refers to the 2024 revision of the Declaration of Helsinki.

Where permitted and appropriate, identify:

• Name of the ethics committee/IRB
• Approval number
• Approval date, if required
• Whether informed consent was obtained
• Whether consent was waived
• The justification for a waiver, where applicable

Example

“The study was approved by the Institutional Review Board of [Institution] (approval no. XXXX). The requirement for informed consent was waived because the study involved retrospective analysis of deidentified clinical data.”

Do not claim that retrospective status automatically eliminates the need for ethical review. Requirements vary by jurisdiction and institution.

For identifiable patient information, ICMJE emphasizes privacy protection and appropriate written informed consent for publication.

6. For Clinical Trials, Document CONSORT Requirements

If your manuscript reports a randomized controlled trial, the Methods section requires substantially more methodological detail.

The CONSORT statement for clinical trials is designed to improve the transparent reporting of randomized trials. Your manuscript should make the trial’s allocation process, interventions, outcomes, and analysis understandable to reviewers and readers.

At minimum, address:

Randomization

Describe:

• Sequence-generation method
• Allocation ratio
• Type of randomization
• Stratification or blocking, if used
• Who generated the allocation sequence

Do not simply write “patients were randomized.”

Explain how randomization was performed.

Allocation concealment

Distinguish allocation concealment from blinding.

Allocation concealment prevents investigators enrolling participants from knowing the upcoming assignment. Blinding concerns who remains unaware of treatment assignment after allocation.

Failure to distinguish these concepts is a common methodological reporting weakness.

Intervention procedures

Describe each intervention sufficiently for replication.

Include:

• Dose
• Route
• Frequency
• Duration
• Timing
• Administration procedure
• Comparator details
• Permitted or prohibited concomitant treatments

For drugs and chemicals, ICMJE recommends precise identification, including generic names, dose, and route of administration.

Sample size

Explain how the target sample size was calculated.

Where appropriate, report:

• Expected effect size
• Alpha level
• Statistical power
• Allocation ratio
• Estimated dropout rate
• Primary outcome used for calculation

A statement such as “the sample size was calculated statistically” is not reproducible.

Trial registration

ICMJE recommends prospective registration of clinical trials in a public registry at or before first participant consent as a condition of consideration by ICMJE journals. Ethics approval does not replace trial registration.

Include the registration identifier where required by the journal.

7. Build a Reproducible Statistical Analysis Section

The statistical analysis section of a medical paper should explain how the research question was translated into statistical tests or models.

At minimum, identify:

• Statistical software and version
• Descriptive statistics
• Primary statistical test or model
• Secondary analyses
• Covariate adjustment
• Missing-data strategy
• Subgroup analyses
• Sensitivity analyses
• Effect estimates
• Confidence intervals
• Statistical significance threshold, when applicable

ICMJE recommends sufficient statistical detail for a knowledgeable reader with access to the original data to assess whether the analysis was appropriate. It also advises authors to quantify findings with appropriate measures of uncertainty and not rely solely on P values.

Report effect size, not just significance

Weak:

“The groups differed significantly (P < .05).”

Stronger:

“The intervention was associated with a 2.4-day reduction in hospital stay (mean difference, −2.4 days; 95% CI, −3.6 to −1.2; P < .001).”

The second version communicates magnitude, precision, and statistical evidence.

Prespecified vs exploratory analyses

Explicitly distinguish:

• Prespecified primary analysis
• Prespecified secondary analyses
• Exploratory analyses
• Subgroup analyses

This distinction is particularly important when multiple analyses are conducted.

Statistical software

Identify the software and version. For example:

“Statistical analyses were performed using R version X.X.X.”

If a specialized package or procedure is central to the analysis, identify it as appropriate.

8. Align the Methods With the Protocol, Registry, and Results

Before submission, conduct a four-way consistency audit:

Protocol ↔ Trial Registry ↔ Methods ↔ Results

Check:

• Sample size
• Primary outcome
• Secondary outcomes
• Intervention groups
• Follow-up period
• Eligibility criteria
• Statistical methods
• Subgroup analyses
• Registration information

Inconsistencies create avoidable editorial questions and may raise concerns about selective reporting.

For clinical trials, ICMJE also requires data-sharing statements for manuscripts reporting trial results and specifies information that should be included about whether deidentified participant-level data will be shared, what will be shared, when, for how long, and under what access conditions.

Also read: Manuscript Editing Services for Journal Submission

9. Address AI Use When It Affects the Research Method

The 2026 ICMJE Recommendations contain expanded guidance on AI in publishing. The current Methods guidance states that authors who use AI technology to conduct a study should describe its use sufficiently to enable replication, including the tool, version, and prompts where applicable.

This is different from simply using generative AI for language polishing.

If AI formed part of the research workflow—for example, automated classification, image analysis, data processing, or another methodological procedure—document it as a methodological component.

Record:

• Tool/system name
• Version
• Purpose
• Relevant settings
• Input data
• Prompts where applicable
• Human validation or oversight
• Reproducibility safeguards

Do not conceal methodological AI use simply because the technology is commercially available.

10. Audit the Methods Section Before Submission

A final Methods audit should test completeness, reproducibility, compliance, and consistency.

A practical editing test

Give your Methods section to a qualified researcher who was not involved in the study.

Ask:

“Could you reproduce the study workflow and statistical analysis from this section without asking the authors what they meant?”

If the answer is no, the Methods section is not yet sufficiently detailed.

Pre-Submission Checklist for a Medical Methods Section

Before submitting your manuscript, confirm that you have:

• Clearly identified the clinical study design.
• Selected the appropriate reporting guideline.
• Defined the study population and eligibility criteria.
• Specified the recruitment or data-collection period.
• Explained the data collection methods.
• Defined primary and secondary outcomes.
• Described instruments, procedures, drugs, doses, and routes where applicable.
• Included the ethics committee/IRB approval statement.
• Explained informed-consent procedures or an approved waiver.
• Documented randomization and allocation concealment for randomized trials.
• Described interventions and comparators sufficiently for replication.
• Explained the sample-size calculation.
• Included clinical trial registration information where applicable.
• Reported statistical software and version.
• Explained the statistical analysis and missing-data strategy.
• Distinguished prespecified and exploratory analyses.
• Reported effect estimates and uncertainty measures where appropriate.
• Checked consistency with the protocol and trial registry.
• Included required data-sharing information.
• Disclosed methodological AI use where applicable.
• Verified every Methods claim against the journal’s author instructions.

Conclusion

A publication-ready Methods section does more than document what researchers did. It establishes methodological transparency, supports reproducibility, demonstrates ethical compliance, and gives reviewers the information needed to evaluate the validity of the study.

Start with the study design. Map the manuscript to the appropriate reporting guideline. Define participants, interventions, outcomes, data collection, ethics procedures, and statistical methods with enough precision to permit independent evaluation. For randomized trials, systematically address CONSORT requirements and verify prospective registration. For every study type, cross-check the Methods against the protocol, registry, Results, tables, and figures.

The strongest medical manuscripts make rigorous research easy to understand—and rigorous Methods writing is central to that process.

For authors preparing a submission, ManuscriptLab’s medical manuscript editing services can provide an additional technical and language review before submission.